Robert Fogel Selected Research

indacaterol

2/2022	Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
1/2019	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
1/2019	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
1/2018	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
1/2018	Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
1/2018	Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
1/2018	Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
1/2018	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
1/2018	Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
12/2017	Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Fogel Research Topics

Disease

29	Chronic Obstructive Pulmonary Disease (COPD) 02/2022 - 09/2014
3	Dyspnea (Shortness of Breath) 08/2017 - 01/2015
3	Pneumonia (Pneumonitis) 01/2017 - 10/2014
2	Asthma (Bronchial Asthma) 09/2022 - 12/2020
1	Chronic Urticaria 01/2022
1	Perennial Allergic Rhinitis 12/2020
1	Seasonal Allergic Rhinitis (Hay Fever) 10/2020
1	Heart Failure 01/2020
1	Osteoporosis 10/2019
1	Type 2 Diabetes Mellitus (MODY) 10/2019
1	Eosinophilia 11/2017
1	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2017
1	Cough 01/2015
1	Atrial Flutter (Flutter, Atrial) 10/2014

Drug/Important Bio-Agent (IBA)

20	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 02/2022 - 10/2014
20	indacaterolIBA 02/2022 - 10/2014
13	Fluticasone (Cutivate)FDA LinkGeneric 10/2019 - 01/2015
12	Salmeterol Xinafoate (Serevent)FDA Link 01/2019 - 01/2015
10	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 10/2014
9	Muscarinic AntagonistsIBA 02/2022 - 01/2015
8	Bronchodilator Agents (Bronchodilators)IBA 01/2020 - 09/2014
7	Tiotropium Bromide (Spiriva)FDA Link 01/2018 - 10/2014
4	Omalizumab (Xolair)FDA Link 09/2022 - 10/2020
4	GoldIBA 01/2020 - 01/2016
2	Fluticasone-Salmeterol Drug Combination (Advair)FDA Link 01/2019 - 01/2017
2	indacaterol-glycopyrronium combinationIBA 01/2015 - 10/2014
1	GadoliniumIBA 02/2022
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2022
1	Immunoglobulin E (IgE)IBA 12/2020
1	AllergensIBA 12/2020
1	Angiotensin Receptor AntagonistsIBA 01/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2018
1	GSK573719IBA 12/2017
1	maleic acid (maleate)IBA 12/2017
1	BromidesIBA 12/2017
1	vilanterolIBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	GlucocorticoidsIBA 01/2016
1	omega-Chloroacetophenone (Mace)IBA 10/2014

Therapy/Procedure

10	Therapeutics 09/2022 - 09/2014
1	Ambulatory Care (Outpatient Care) 01/2020